TVM Capital Life Science (TVM) is committing up to $24 million for a development program to advance NE-DHA-SBT-1214, Dr. Iwao Ojima's compound, to market for the treatatment of colorectal cancer and other solid tumors. (read more one) (read more two)
ICB&DD 16th Annual Symposium
First full in-person Annual Symposium since 2019 (Read more)
Congratulations to ICB&DD Symposium Poster Award Winners
Yu-Ching Chen, graduate student in Dr. Nicole Sampson's research group, Department of Chemistry (Read more)
Jinal Patel, graduate student in Dr. Hyungjin Kim's research group, Department of Pharmacological Sciences (Read more)
Dr. Nivea Pereira de Sa, postdoctoral research associate in Dr. Maurizio Del Poeta's research group, Department of Microbiology and Immunology (Read more)
Congratulations to Dr. Michael Airola and his Graduate Student, Recipients of SBU's First HHMI Gilliam Fellowship
ICB&DD Member Dr. Micahel Airola and his graduate student, Franceine Welcome have won the first Stony Brook University's Howard Hughes Medical Institute (HHMI) Gilliam Fellowship for Advanced Study. (Read more)
Dr. Makoto Fujita, Inaugural Award Lecturer of the Ojima Distinguished Lectureship Award in Chemistry
Dr. Makoto Fujita, Distinguished Professor from The University of Tokyo gave the inaugural award lecture at the Ojima Distinguished Lectureship Award in Chemistry on April 29 at the Wang Center, SBU.
Message from the Director
Dr. Iwao Ojima, Distinguished Professor and Director, ICB&DD
Welcome to the Institute of Chemical Biology & Drug Discovery
The primary objective of ICB&DD is to establish a world-class “Center of Excellence” in chemical biology and drug discovery at Stony Brook. The rapid and impressive advancement of chemical biology in the last decades clearly demonstrated that solutions for vast majority of medical problems rely on the understanding of the molecular basis of diseases, therapeutic targets, drug actions, and drug resistance. ICB&DD promotes highly productive interdisciplinary and multidisciplinary research bridging the West, East and South campuses as well as Brookhaven National Laboratory to attack major and significant biomedical problems to find solutions including the discovery of novel therapeutic drugs. ICB&DD significantly contributes to the advancement of a truly comprehensive biomedical research enterprise from molecular science to clinic at Stony Brook.
ICB&DD 2022 SYMPOSIUM